Trial Profile
A postmarketing surveillance study assessing safety and efficacy of gemcitabine and erlotinib combination therapy in patients with metastatic pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms POLARIS
- Sponsors Chugai Pharmaceutical
- 15 Dec 2017 New trial record